417 related articles for article (PubMed ID: 26055532)
1. Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness.
Macerola E; Loggini B; Giannini R; Garavello G; Giordano M; Proietti A; Niccoli C; Basolo F; Fontanini G
Virchows Arch; 2015 Aug; 467(2):177-84. PubMed ID: 26055532
[TBL] [Abstract][Full Text] [Related]
2. Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma.
Heidenreich B; Nagore E; Rachakonda PS; Garcia-Casado Z; Requena C; Traves V; Becker J; Soufir N; Hemminki K; Kumar R
Nat Commun; 2014 Feb; 5():3401. PubMed ID: 24569790
[TBL] [Abstract][Full Text] [Related]
3.
Bai X; Kong Y; Chi Z; Sheng X; Cui C; Wang X; Mao L; Tang B; Li S; Lian B; Yan X; Zhou L; Dai J; Guo J; Si L
Clin Cancer Res; 2017 Oct; 23(20):6120-6127. PubMed ID: 28720667
[No Abstract] [Full Text] [Related]
4. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients.
Jin L; Chen E; Dong S; Cai Y; Zhang X; Zhou Y; Zeng R; Yang F; Pan C; Liu Y; Wu W; Xing M; Zhang X; Wang O
Oncotarget; 2016 Apr; 7(14):18346-55. PubMed ID: 26943032
[TBL] [Abstract][Full Text] [Related]
5. Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas.
Li Y; Cheng HS; Chng WJ; Tergaonkar V
Proc Natl Acad Sci U S A; 2016 Dec; 113(50):14402-14407. PubMed ID: 27911794
[TBL] [Abstract][Full Text] [Related]
6. Clinical, environmental and histological distribution of BRAF, NRAS and TERT promoter mutations among patients with cutaneous melanoma: a retrospective study of 563 patients.
Manrique-Silva E; Rachakonda S; Millán-Esteban D; García-Casado Z; Requena C; Través V; Kumar R; Nagore E
Br J Dermatol; 2021 Mar; 184(3):504-513. PubMed ID: 32506424
[TBL] [Abstract][Full Text] [Related]
7. Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.
Yang S; Leone DA; Biswas A; Deng A; Jukic D; Singh R; Sundram U; Mahalingam M
Hum Pathol; 2018 Dec; 82():206-214. PubMed ID: 30120967
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity of BRAF, NRAS, and TERT Promoter Mutational Status in Multiple Melanomas and Association with MC1R Genotype: Findings from Molecular and Immunohistochemical Analysis.
Pellegrini C; Di Nardo L; Cipolloni G; Martorelli C; De Padova M; Antonini A; Maturo MG; Del Regno L; Strafella S; Micantonio T; Leocata P; Peris K; Fargnoli MC
J Mol Diagn; 2018 Jan; 20(1):110-122. PubMed ID: 29061376
[TBL] [Abstract][Full Text] [Related]
9. Coexistence of
Rusinek D; Pfeifer A; Krajewska J; Oczko-Wojciechowska M; Handkiewicz-Junak D; Pawlaczek A; Zebracka-Gala J; Kowalska M; Cyplinska R; Zembala-Nozynska E; Chekan M; Chmielik E; Kropinska A; Lamch R; Jurecka-Lubieniecka B; Jarzab B; Czarniecka A
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30200646
[No Abstract] [Full Text] [Related]
10. TERT Promoter Mutational Status in the Management of Cutaneous Melanoma: Comparison with Sentinel Lymph Node Biopsy.
Martins F; Martins C; Fernandes MS; Andrade MI; Lopes JM; Soares P; Pópulo H
Dermatology; 2022; 238(3):507-516. PubMed ID: 34569488
[TBL] [Abstract][Full Text] [Related]
11. Varying Mutational Alterations in Multiple Primary Melanomas.
Egberts F; Bohne AS; Krüger S; Hedderich J; Rompel R; Haag J; Röcken C; Hauschild A
J Mol Diagn; 2016 Jan; 18(1):75-83. PubMed ID: 26607775
[TBL] [Abstract][Full Text] [Related]
12.
Tanaka A; Matsuse M; Saenko V; Nakao T; Yamanouchi K; Sakimura C; Yano H; Nishihara E; Hirokawa M; Suzuki K; Miyauchi A; Eguchi S; Yoshiura KI; Yamashita S; Nagayasu T; Mitsutake N
Thyroid; 2019 Aug; 29(8):1105-1114. PubMed ID: 31286848
[No Abstract] [Full Text] [Related]
13. Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas.
Vazquez Vde L; Vicente AL; Carloni A; Berardinelli G; Soares P; Scapulatempo C; Martinho O; Reis RM
Melanoma Res; 2016 Apr; 26(2):93-9. PubMed ID: 26709572
[TBL] [Abstract][Full Text] [Related]
14. TERT promoter mutations and BRAF mutations are rare in sporadic, and TERT promoter mutations are absent in NF1-related malignant peripheral nerve sheath tumors.
Dubbink HJ; Bakels H; Post E; Zwarthoff EC; Verdijk RM
J Neurooncol; 2014 Nov; 120(2):267-72. PubMed ID: 25035100
[TBL] [Abstract][Full Text] [Related]
15. BRAF mutation screening in melanoma: is sentinel lymph node reliable?
Nardin C; Puzenat E; Prétet JL; Algros MP; Doussot A; Puyraveau M; Mougin C; Aubin F
Melanoma Res; 2015 Aug; 25(4):328-34. PubMed ID: 26020488
[TBL] [Abstract][Full Text] [Related]
16. TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.
Thielmann CM; Matull J; Zaremba A; Murali R; Chorti E; Lodde G; Jansen P; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Kretz J; Möller I; Sucker A; Paschen A; Livingstone E; Zimmer L; Hadaschik E; Ugurel S; Schadendorf D; Griewank KG
Eur J Cancer; 2022 Jan; 161():99-107. PubMed ID: 34936949
[TBL] [Abstract][Full Text] [Related]
17. A primary melanoma and its asynchronous metastasis highlight the role of BRAF, CDKN2A, and TERT.
Hosler GA; Davoli T; Mender I; Litzner B; Choi J; Kapur P; Shay JW; Wang RC
J Cutan Pathol; 2015 Feb; 42(2):108-17. PubMed ID: 25407517
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma.
Siroy AE; Aung PP; Torres-Cabala CA; Tetzlaff MT; Nagarajan P; Milton DR; Curry JL; Ivan D; Prieto VG
Hum Pathol; 2017 Jan; 59():48-54. PubMed ID: 27666765
[TBL] [Abstract][Full Text] [Related]
19. BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases.
Öztürk Sari Ş; Yilmaz İ; Taşkin OÇ; Narli G; Şen F; Çomoğlu Ş; Firat P; Bİlgİç B; Yilmazbayhan D; Özlük Y; Büyükbabanİ N
Pathology; 2017 Jan; 49(1):55-61. PubMed ID: 27914687
[TBL] [Abstract][Full Text] [Related]
20. Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.
Song YS; Lim JA; Choi H; Won JK; Moon JH; Cho SW; Lee KE; Park YJ; Yi KH; Park DJ; Seo JS
Cancer; 2016 May; 122(9):1370-9. PubMed ID: 26969876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
